Home » Stocks » HAE

Haemonetics Corporation (HAE)

Stock Price: $59.06 USD -0.24 (-0.40%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 3.01B
Revenue (ttm) 870.46M
Net Income (ttm) 79.47M
Shares Out 50.85M
EPS (ttm) 1.55
PE Ratio 38.10
Forward PE 22.32
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $59.06
Previous Close $59.30
Change ($) -0.24
Change (%) -0.40%
Day's Open 59.11
Day's Range 57.93 - 59.39
Day's Volume 523,486
52-Week Range 49.26 - 142.11

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON, July 9, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2022 financial results at 6:00 am EDT on Wednesday, Augus...

2 weeks ago - PRNewsWire

We believe that the stock price of Haemonetics, best known for its blood and plasma supplies and services, is undervalued at current levels of $63. HAE stock is down 27% from the levels of around $86 it...

4 weeks ago - Forbes

The stock price of Haemonetics, best known for its blood and plasma supplies and services, has seen a large 13% drop over the last ten trading days, and we believe the stock will likely rebound in the n...

2 months ago - Forbes

Haemonetics' (HAE) fourth-quarter fiscal 2021 revenues declined 5.6% year over year due to the pandemic.

2 months ago - Zacks Investment Research

One analyst upgrade in particular seemed to bring back the bulls.

2 months ago - The Motley Fool

Investors don't seem to be buying the company's rosy 2022 guidance.

2 months ago - The Motley Fool

Haemonetics (HAE) delivered earnings and revenue surprises of -31.34% and -0.06%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Haemonetics (NYSE:HAE) rose 2.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 33.33% over the past year to $0.46, which missed th...

2 months ago - Benzinga

BOSTON, May 13, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal 2021, which ended April 3, 2021, are available on its Investor Rel...

2 months ago - PRNewsWire

Continued benefits from the NexSys device and NexLynk DMS along with robust TEG devices sales are expected to have contributed to Haemonetics (HAE) fourth-quarter top line.

2 months ago - Zacks Investment Research

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

BOSTON, April 29, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, annou...

2 months ago - PRNewsWire

BOSTON, April 23, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish fourth quarter and fiscal year 2021 financial results at 6:00 am EDT on Thursday, ...

3 months ago - PRNewsWire

The stock price of Haemonetics, best known for its blood and plasma supplies and services, plunged over 36% in a single trading session yesterday. This can be attributed to one of its large customers - ...

3 months ago - Forbes

BOSTON, April 19, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) ("Haemonetics" or the "Company"), a global medical technology company focused on delivering innovative medical solutions to dri...

3 months ago - PRNewsWire

Haemonetics stock, best known for its blood and plasma supplies and services, has fallen by 3.5% in the last week, while it is down 7% over the last ten days. HAE stock has been on a decline since it re...

3 months ago - Forbes

Investor are optimistic about Haemonetics (HAE) on its continued Plasma franchise growth and huge potential of Hemostasis Management franchise.

3 months ago - Zacks Investment Research

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

BOSTON, March 2, 2021 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $435,000,000 aggregate principal amount of 0.00% Convertible Seni...

4 months ago - PRNewsWire

BOSTON, March 1, 2021 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced its intention to offer, subject to market and other conditions, $425,000,000 aggregate principal...

4 months ago - PRNewsWire

BOSTON, Feb. 26, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the Jefferies Plasma Summit on Thursday, March 11, 2021, at 10:45...

4 months ago - PRNewsWire

Haemonetics (HAE) third-quarter fiscal 2021 revenues declined 7.2% year over year to $240.4 million, improving 14.7% sequentially.

5 months ago - Zacks Investment Research

Haemonetics Corporation (HAE) CEO Christopher Simon on Q3 2021 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Haemonetics (HAE) delivered earnings and revenue surprises of 19.12% and 6.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of Haemonetics (NYSE:HAE) were flat in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 13.83% year over year to $0.81, which beat the estimate ...

5 months ago - Benzinga

BOSTON, Feb. 2, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal 2021, which ended December 26, 2020, are available on its Investor ...

5 months ago - PRNewsWire

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

BOSTON, Jan. 22, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) ("Haemonetics"), a global medical technology company focused on delivering innovative medical solutions to drive better patient ...

6 months ago - PRNewsWire

BOSTON, Jan. 20, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) ("Haemonetics"), a global medical technology company focused on delivering innovative medical solutions to drive better patient ...

6 months ago - PRNewsWire

Haemonetics (HAE) is optimistic about maintaining a robust product portfolio amid the pandemic-led business disruptions.

6 months ago - Zacks Investment Research

BOSTON, Jan. 5, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2021 financial results at 6:00 am EDT on Tuesday, Februar...

6 months ago - PRNewsWire

With the Covid vaccine rollout accelerating, these companies will be big beneficiaries in the year ahead.

Other stocks mentioned: CNNWF, ICAGY, SSEZY, VMC
7 months ago - Forbes

Haemonetics has sustainable growth levers in place that are underscored by key product offerings and recent liquidity preservation measures. The company remains insulated from larger names via their ext...

7 months ago - Seeking Alpha

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?

7 months ago - Zacks Investment Research

We believe that Haemonetics stock, best known for its blood and plasma supplies and services, is a good buying opportunity at the present time. HAE stock trades near $113 currently and it is, in fact, d...

7 months ago - Forbes

Haemonetics (HAE) invests in clinical trials that build evidence for its hemostasis management products.

7 months ago - Zacks Investment Research

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities ...

8 months ago - Insider Monkey

Haemonetics' (HAE) second-quarter fiscal 2021 results reflect impressive performance by Hospital segment despite dismal overall performance during the coronavirus-led crisis.

8 months ago - Zacks Investment Research

Haemonetics Corporation (HAE) CEO Chris Simon on Q2 2021 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Haemonetics (HAE) delivered earnings and revenue surprises of 24.00% and 3.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

  Shares of Haemonetics (NYSE:HAE) fell 0.1% in pre-market trading after the company reported Q2 results.

8 months ago - Benzinga

BOSTON, Nov. 4, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its second quarter fiscal 2021, which ended September 26, 2020, are available on its Investor...

8 months ago - PRNewsWire

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

BOSTON, Oct. 6, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2021 financial results at 6:00 am EDT on Wednesday, Novem...

9 months ago - PRNewsWire

BOSTON, Oct. 2, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, toda...

9 months ago - PRNewsWire

With the third quarter of what has proven to be a remarkable 2020 coming to a close, many of the firms we cover across Wall Street already are looking to the stretch run of the year and at what should b...

Other stocks mentioned: CI, HZNP, VRTX, BTAI
9 months ago - 24/7 Wall Street

BOSTON, Sept. 9, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 18th Annual Morgan Stanley Virtual Global Healthcare Conferen...

10 months ago - PRNewsWire

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?

10 months ago - Zacks Investment Research

Shares of blood transfusion and plasma provider Haemonetics Inc. HAE, +2.34% were off their highs on Monday, after Needham analysts said news of an emergency use authorization for convalescent plasma as...

10 months ago - Market Watch

Haemonetics Corporation (HAE) CEO Chris Simon on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

About HAE

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides autom... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
May 9, 1991
CEO
Christopher Simon
Employees
2,708
Stock Exchange
NYSE
Ticker Symbol
HAE
Full Company Profile

Financial Performance

In 2021, Haemonetics's revenue was $870.46 million, a decrease of -11.94% compared to the previous year's $988.48 million. Earnings were $79.47 million, an increase of 3.85%.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Haemonetics stock is "Buy." The 12-month stock price forecast is 80.29, which is an increase of 35.95% from the latest price.

Price Target
$80.29
(35.95% upside)
Analyst Consensus: Buy